Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease who are undergoing dialysis.

Next Previous
Search
Trial Profile

Phase IIa trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease who are undergoing dialysis.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 Dec 2014 Full data analysis of the trial is expected to be completed by the end of the third quarter of 2015, according to an Aerie Pharmaceuticals media release.
  • 02 Dec 2014 Results for the second cohort are expected in the first quarter of 2015, according to a Xenetic Biosciences media release.
  • 02 Dec 2014 Dosing of the second cohort has been completed and enrolment in the third cohort has begun, according to a Xenetic Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top